CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Absci Q3 revenue misses estimates, net loss widens on R&D spends

By Reuters News


Overview

  • U.S. biopharma company's Q3 revenue fell and missed analyst expectations

  • Net loss widened in Q3 as R&D expenses rose for internal programs

  • Company appointed Gerry Muhle as Chief Commercial Officer to build commercial infrastructure


Outlook

  • Absci expects 13-week interim proof-of-concept data for ABS-201 in PHL in Dec 2026

  • Company anticipates full 26-week proof-of-concept data for ABS-201 in early 2027

  • Absci plans to initiate Phase 2 STORYLINE trial for ABS-201 in endometriosis in mid-2027


Result Drivers

  • R&D SPENDING - Co said higher research and development expenses were mainly due to advancement of internal programs, including direct costs for ABS-201 clinical and nonclinical development

  • SG&A COSTS - Selling, general, and administrative expenses rose due to increased stock-based compensation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$304,000

$727,130 (8 Analysts)

Q3 Net Loss

$33.30 mln

Q3 Loss Per Basic Share

$0.19

Q3 Operating Expenses

$35.30 mln

Q3 Operating Income

-$34.99 mln

Q3 Pretax Loss

$33.28 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Absci Corp is $15.00, about 48.2% above its November 11 closing price of $10.12


Reuters Recommended Reads

  • Nov 10 - Biotech firm PepGen's Q3 net loss widens as R&D expenses rise

  • Nov 9 - Structure Therapeutics Q3 loss widens on higher R&D costs

  • Nov 10 - Palisade Bio Q3 loss widens on higher R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.